BeiGene’s first foray into cell therapy has ended without bearing any fruit. The cancer drugmaker disclosed in a securities filing Monday that it has parted ways with Shoreline Biosciences more than three years after first agreeing to develop NK cell therapies together.
Under the 2021 deal, BeiGene paid $45 million upfront to collaborate with Shoreline on anti-cancer cell therapies against four targets using the latter’s iPSC NK cell technology.
The terminated partnership leaves BeiGene’s pipeline bereft of cell therapies to treat cancer, though investors don’t seem to mind. Stellar sales of Brukinsa (zanubrutinib) and Tevimbra (tislelizumab) – to which Novartis recently handed back its rights – pushed the firm’s 2023 revenues to an all-time high, and its stock gained more than 3% Monday.
The Chinese firm reported 2023 revenues of $2.2 billion, up 75% from its 2022 product sales of $1.4 billion, roughly in-line with analyst expectations.
Full-year global sales of Brukinsa reached $1.3 billion last year, more than double its 2022 revenues of $564.7 million, with that figure expected to only increase as US sales continue to grow.
Revenue could receive a bump if the FDA approves Brukinsa in combination with obinutuzumab to treat relapsed/refractory follicular lymphoma in adults who have received at least two prior lines of systemic therapy; the drug received European approval of the indication in November. A decision is expected in March, and if positive, would grant the BTK inhibitor the broadest label in the class.
Despite facing turmoil from a terminated agreement with Novartis, anti-PD-1 antibodyTevimbra brought in $536.6 million last year, up from its 2022 sales of $422.9 million.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.